TAA-specific CTLs

BIOLOGICAL4 trials

Sponsors

Baylor College of Medicine

Conditions

Breast CancerHodgkins LymphomaMultiple MyelomaNon Hodgkins LymphomaRhabdomyosarcoma

Phase 1

TAA-Specific CTLS for Solid Tumors (TACTASOM)

CompletedNCT02239861

Baylor College of MedicineRhabdomyosarcoma

Start: 2015-04-30End: 2022-04-07Updated: 2022-04-12

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

Active, not recruitingNCT02291848

Baylor College of MedicineMultiple Myeloma

Start: 2015-04-01End: 2027-12-22Target: 36Updated: 2026-08-05

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).

WithdrawnNCT05134740

Baylor College of MedicineHodgkins Lymphoma, Non Hodgkins Lymphoma

Start: 2024-04-30End: 2030-02-01Updated: 2024-10-22

Phase 2

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

CompletedNCT03093350

Baylor College of MedicineBreast Cancer

Start: 2017-10-10End: 2024-08-23Updated: 2025-08-29

Related Papers

Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma

Blood2018-11-292 citations

Adoptive Transfer of Multi-Tumor Antigen Specific T Cells as Treatment for Patients with Multiple Myeloma

Biology of Blood and Marrow Transplantation2017-02-2216 citations

T Cell Therapy for Multiple Myeloma

Biology of Blood and Marrow Transplantation2016-02-18